Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 19 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Anal human papillomavirus infection in HIV-infected persons

Anal human papillomavirus infection and anal squamous intraepithelial lesions may be acquired in the absence of anal intercourse in HIV-positive men, find researchers in the latest issue of the Annals of Internal Medicine.

News image

fiogf49gjkf04

Anal cancer and its precursor lesion, anal squamous intraepithelial lesions (SILs), are associated with human papillomavirus (HPV) infection.

Anal HPV infection and anal SIL are common in HIV-positive men who have sex with men. Receptive anal intercourse has been presumed to be the mode of acquisition of HPV.

46% of the 50 heterosexual men studied had anal HPV infection.
Annals of Internal Medicine

In this study, researchers from France and the United States assessed the prevalence and risk factors for anal HPV infection and anal SIL in HIV-positive men with no history of anal intercourse.

The research team studied 50 HIV-positive male injection drug users with no history of anal intercourse. They also assessed 67 HIV-infected men who had sex with men. Study subjects were evaluated using cytologic, histologic, and anal HPV DNA testing.

The researchers found that 46% of the 50 heterosexual men had anal HPV infection. In addition, low-grade SIL (LSIL) was found in 16% of these patients and high-grade SIL (HSIL) in 18%.

The team also determined that of the 67 men who had sex with men, anal HPV infection was found in 85%, LSIL in 49%, and HSIL in 12 patients 18%.

They identified risk factors for abnormal anal cytologic or histologic findings in injection drug users using univariate analysis. Risks included CD4+ cell counts less than 250 × 106 cells/l (odds ratio (OR) 5.7), plasma HIV RNA viral load greater than 1.7 log copies/ml (OR 8.9), previous AIDS-defining event (OR 4.3), and anal HPV detection (OR 5.7).

Risk factors among men who had sex with men included having more than 10 lifetime receptive anal intercourse episodes (OR 5.6) and anal HPV detection (OR 8.7).

Dr Christophe Piketty's team concluded, "Anal HPV infection and anal SIL may be acquired in the absence of anal intercourse in HIV-positive men".

"The prevalence of HSIL is high among HIV-positive injection drug users."

"All HIV-positive men with CD4+ cell counts less than 500 × 106 cells/L, regardless of history of anal intercourse, should be considered for anal cytologic screening.

"However, additional studies are needed to determine the efficacy of this procedure to prevent anal cancer in these populations."

Ann Intern Med 2003; 138: 453-9
24 March 2003

Go to top of page Email this page Email this page to a colleague

 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Management of hemorrhoids in the USA
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis
 24 January 2018 
Ethnicity influences phenotype in IBD
 24 January 2018 
Bariatric surgery vs medical obesity treatment
 23 January 2018 
Atrophic gastritis after H. pylori eradication
 23 January 2018 
Ectopic pregnancy in women with IBD
 23 January 2018 
Celiac disease in IBS in the USA

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us